MAHWAH, N.J., Aug. 4, 2023 /PRNewswire/ -- Stryker (NYSE: SYK), one of the world's largest medical technology companies, announced the launch of a nationwide, direct-to-patient marketing campaign, "Scan. Plan. Mako Can." Through this campaign, Stryker aims to continue to drive patient awareness of Mako SmartRobotics™, an innovative option for those needing joint replacement surgery due to arthritis of the knee or hip.
"'Scan. Plan. Mako Can.' is rooted in the foundation of Mako SmartRobotics™," said Don Payerle, president of Stryker's Joint Replacement division. "We have an unwavering commitment to revolutionizing joint replacement technology and enabling surgeons to achieve enhanced outcomes for their patients. We are eager to share this campaign with patients experiencing joint pain so they can seek care and begin their journey towards returning to the activities they love."
CT-based planning is an integral component of Mako SmartRobotics™ that allows surgeons to know more about their patient's anatomy and the procedure prior to surgery. Mako's innovative AccuStop™ haptic technology enables surgeons to execute their plans with precision1-3, helping to minimize tissue disruption.4-6 Mako SmartRobotics™ has demonstrated better outcomes, like less pain and quicker recovery times, compared to manual joint replacement surgery.7-9
Additionally, by enabling products like Mako with digital capabilities, known as Advanced Digital Healthcare, Stryker is generating insights to drive improved clinical, operational and financial outcomes across the continuum of care.
The omnichannel "Scan. Plan. Mako Can." campaign will come to life through different assets and various media channels, including linear TV, streaming TV, social media, YouTube, programmatic/endemic and paid search. "Scan. Plan. Make Can." will begin rolling out to the public today.
Those living with joint pain are encouraged to speak with their healthcare professional about available treatment plans and whether joint replacement surgery is right for them. More information about Mako SmartRobotics™ is available at MakoCan.com.
All surgery carries risk. Surgeons must rely on their own professional clinical judgment when deciding whether to utilize a particular technology when treating a patient in their own practice. Stryker does not dispense medical advice and recommends that surgeons be trained in the use of any technology before using it in surgery. Not all patients will have the same postoperative recovery and activity level. Individual results vary.
About Stryker
Stryker is one of the world's leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Medical and Surgical, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually. More information is available at www.stryker.com.
Last Trade: | US$358.92 |
Daily Change: | 0.92 0.26 |
Daily Volume: | 778,203 |
Market Cap: | US$136.780B |
August 22, 2024 August 12, 2024 August 06, 2024 July 31, 2024 July 30, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORESurmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB